372 related articles for article (PubMed ID: 25557211)
1. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.
Luger T; Boguniewicz M; Carr W; Cork M; Deleuran M; Eichenfield L; Eigenmann P; Fölster-Holst R; Gelmetti C; Gollnick H; Hamelmann E; Hebert AA; Muraro A; Oranje AP; Paller AS; Paul C; Puig L; Ring J; Siegfried E; Spergel JM; Stingl G; Taieb A; Torrelo A; Werfel T; Wahn U
Pediatr Allergy Immunol; 2015 Jun; 26(4):306-15. PubMed ID: 25557211
[TBL] [Abstract][Full Text] [Related]
2. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
4. Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus.
Luger T; Augustin M; Lambert J; Paul C; Pincelli C; Torrelo A; Vestergaard C; Wahn U; Werfel T
Pediatr Allergy Immunol; 2021 Apr; 32(3):414-424. PubMed ID: 33251600
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm.
Luger T; De Raeve L; Gelmetti C; Kakourou T; Katsarou A; Lambert J; Morren MA; Oranje A; Ruer M; Serdaroglu S; Torrelo A; Werfel T
Eur J Dermatol; 2013; 23(6):758-66. PubMed ID: 24185493
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on topical pimecrolimus in atopic dermatitis.
Wellington K; Jarvis B
Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Breuer K; Werfel T; Kapp A
Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
[TBL] [Abstract][Full Text] [Related]
8. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Wellington K; Jarvis B
Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Siegfried EC; Jaworski JC; Kaiser JD; Hebert AA
BMC Pediatr; 2016 Jun; 16():75. PubMed ID: 27267134
[TBL] [Abstract][Full Text] [Related]
10. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.
Frankel A; Sohn A; Patel RV; Lebwohl M
J Drugs Dermatol; 2011 Jun; 10(6):666-72. PubMed ID: 21637908
[TBL] [Abstract][Full Text] [Related]
11. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.
Reitamo S; Remitz A; Kyllönen H; Saarikko J
Am J Clin Dermatol; 2002; 3(6):381-8. PubMed ID: 12113647
[TBL] [Abstract][Full Text] [Related]
12. Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.
Prucha H; Schnopp C; Akdis C; Lauener R; Wollenberg A; Ring J; Traidl-Hoffmann C
Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1507-16. PubMed ID: 23876065
[TBL] [Abstract][Full Text] [Related]
13. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
14. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
15. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Werfel T
J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.
Garside R; Stein K; Castelnuovo E; Pitt M; Ashcroft D; Dimmock P; Payne L
Health Technol Assess; 2005 Jul; 9(29):iii, xi-xiii,1-230. PubMed ID: 16022804
[TBL] [Abstract][Full Text] [Related]
17. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
19. Position statement: topical calcineurin inhibitors in atopic dermatitis.
Remitz A; De Pità O; Mota A; Serra-Baldrich E; Vakirlis E; Kapp A
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2074-2082. PubMed ID: 30288799
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.
Ho VC; Gupta A; Kaufmann R; Todd G; Vanaclocha F; Takaoka R; Fölster-Holst R; Potter P; Marshall K; Thurston M; Bush C; Cherill R
J Pediatr; 2003 Feb; 142(2):155-62. PubMed ID: 12584537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
